← All stocks

Structure Therapeutics Inc.

GPCR No buying or selling
CIK 0001888886 #1593 in the set updated 21 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

14 insiders · 8 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
FMR LLC entity
10% owner
4,769,404
2.23%
Farid Ramy
Director
3,260,495
1.52%
+24.5%
Yoon Jun
CHIEF FINANCIAL OFFICER
1,401,656
0.6552%
+31.8%
Stevens Raymond C
CHIEF EXECUTIVE OFFICER
1,401,593
0.6552%
+31.8%
FIL Ltd entity
See Remark 1
624,239
0.2918%
Coll Crespo Blas
CHIEF MEDICAL OFFICER
280,878
0.1313%
+2,241%
Lin Xichen
CHIEF SCIENTIFIC OFFICER
228,960
0.1070%
Lang Matthew
COO & GC
184,614
0.0863%
Hall Ashley
Chief Development Officer
155,187
0.0725%
Berrios John Joseph
Chief Commercial Officer
140,766
0.0658%
Ma Yingli
CHIEF TECHNOLOGY OFFICER
139,917
0.0654%
WELCH DANIEL G
Director
123,508
0.0577%
Bach Mark Allen
CHIEF MEDICAL OFFICER
26,235
0.0123%
BVF PARTNERS L P/IL entity
10% owner
0
0.0000%
−100.0%
Insider
Date
Role
Action
Shares
Price
Amount
Lin Xichen
1 Sep 2026
CHIEF SCIENTIFIC OFFICER
Exercised, kept
17,817
$0.34
$6.06K
Lin Xichen
18 Aug 2026
CHIEF SCIENTIFIC OFFICER
Exercised, kept
11,817
$0.34
$4.02K
Lin Xichen
4 Aug 2026
CHIEF SCIENTIFIC OFFICER
Exercised, kept
11,817
$0.34
$4.02K
Lin Xichen
14 Jul 2026
CHIEF SCIENTIFIC OFFICER
Exercised, kept
23,634
$0.34
$8.04K
Lin Xichen
25 Jun 2026
CHIEF SCIENTIFIC OFFICER
Exercised, kept
23,634
$0.34
$8.04K
Stevens Raymond C
12 Jun 2024
CHIEF EXECUTIVE OFFICER
Exercised, kept
50,001
$0.48
$24.00K
Stevens Raymond C
12 Jun 2024
CHIEF EXECUTIVE OFFICER
Exercised, kept
99,999
$0.39
$39.00K
Lin Xichen
3 Jun 2024
CHIEF SCIENTIFIC OFFICER
Exercised, kept
106,200
$0.34
$36.11K

What was left out

Form 4 filings counted 87
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 24,199,738
History held since 6 Feb 2023